Trial watch: DNA-based vaccines for oncological indications. (2nd December 2017)

• Record Type: Journal Article
• Authors: Pierini, Stefano; Perales-Linares, Renzo; Uribe-Herranz, Mireia; Pol, Jonathan G.; Zitvogel, Laurence; Kroemer, Guido; Facciabene, Andrea; Galluzzi, Lorenzo
• Is Part Of: Oncoimmunology. Volume 6:Number 12(2017)
• Publication Date: 2017-12-02
• Subjects: adenovirus -- cancer testis antigens -- CTLA4 -- electroporation -- PADRE -- PD-1 -- TRICOM; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2017.1398878
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: DNA-based vaccination is a promising approach to cancer immunotherapy. DNA-based vaccines specific for tumor-associated antigens (TAAs) are indeed relatively simple to produce, cost-efficient and well tolerated. However, the clinical efficacy of DNA-based vaccines for cancer therapy is considerably limited by central and peripheral tolerance. During the past decade, considerable efforts have been devoted to the development and characterization of novel DNA-based vaccines that would circumvent this obstacle. In this setting, particular attention has been dedicated to the route of administration, expression of modified TAAs, co-expression of immunostimulatory molecules, and co-delivery of immune checkpoint blockers. Here, we review preclinical and clinical progress on DNA-based vaccines for cancer therapy.